Does Semaglutide Cause Muscle Loss?
US$ 21.45
sar425899 sanofi dual glp-1 glucagon agonist Receptor occupancy of glucagon-like peptide 1/glucagon receptor in individuals with type 2 diabetes Glucagon agonism in the treatment
Description
Karlsson, T., Hadizadeh, F., Rask-Andersen, M., Johansson, & Ek, W
Patients now have more flexibility to choose between injectable or oral GLP-1 treatment options
BMJ (2015) 350:g7607
Additionally, GLP-1 RAs should be considered in overweight or obese patients to reduce weight (class IIa, level B)
Stay Informed Subscribe to the ISMP Canada Safety Bulletins and Newsletters
